Amgen Stock Dives

Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.
The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could be remain
Amgen shows 20% weight loss in once-monthly injectable MariTide
Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.
Amgen posts mid-stage data for weight loss therapy
Amgen (AMGN) stock slips as company posts mid-stage trial data for weight loss therapy MariTide. Rivals Eli Lilly (LLY) and Novo Nordisk (NVO) gain. Read more here.
Amgen’s weight-loss injection cuts up to 20% in a year
Amgen Inc (NASDAQ: AMGN) says patients on its weight-loss injection in a mid-stage trial weighed up to 20% less on average after a year. The biopharmaceutical giant is convinced its treatment will help lower body weight even further upon continued consumption (beyond 52 weeks) as it did not observe a plateau in the Phase II study.
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period.
Amgen's experimental jab causes 20 per cent weight loss in early results
Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in those with diabetes after a year in a phase 2 trial. Despite higher discontinuation rates compared to other drugs,
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen price target lowered to $330 from $360 at RBC Capital
RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...